tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Asad Haider, 8 are a HOLD (47.06%), 1 are a SELL (5.88%), 8 are a BUY (47.06%).
Analyst Asad Haider, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 92.22% that have a potential upside of 21.03% achieved within 179 days.
Asad Haider’s has documented 38 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BNTX, BioNTech SE at 16-Jan-2026.
Analyst best performing recommendations are on NAMS (NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES).
The best stock recommendation documented was for NAMS (NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES) at 12/2/2025. The price target of $37 was fulfilled within 1 day with a profit of $1.33 (3.47%) receiving and performance score of 34.7.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 06-Feb-2026
$75
$9.69 (14.84%)
$72
4 days ago
(31-Jul-2026)
4/17 (23.53%)
$9.69 (14.84%)
1017
Hold Since 08-Dec-2021
$65
$-0.31 (-0.47%)
$60
4 days ago
(31-Jul-2026)
11/13 (84.62%)
$-0.31 (-0.47%)
275
Hold Since 18-Nov-2022
$64
$-1.31 (-2.01%)
$60
4 days ago
(31-Jul-2026)
10/13 (76.92%)
$-1.31 (-2.01%)
172
Buy Since 26-Jul-2021
$70
$4.69 (7.18%)
$65
4 days ago
(31-Jul-2026)
2/11 (18.18%)
$4.69 (7.18%)
698
Buy Since 18-Aug-2015
$73
$7.69 (11.77%)
$70
4 days ago
(31-Jul-2026)
7/18 (38.89%)
$7.69 (11.77%)
971
What Year was the first public recommendation made by Asad Haider?
